AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukemia #EHA2019

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic leukaemia #EHA2019

Shots:

  • The P-III ASCEND study results involve assessing of Calquence as monothx. (100mg, bid) vs Rituximab + Idelalisib (IdR) or Bendamustine (BR) in 310 patients in a ratio (1:1) with CLL prior treated with 1L therapy
  • The P-III ASCEND study results: @16.1mos. improvement in PFS; reduction in risk of disease progression by 69%; @12mos. no diseases progression (88% vs 68%), no news safety signals are observed
  • Calquence is a BTK inhibitor, covalently binding with BTK, inhibiting its activity in B-cell and has received FDA’s accelerated approval in Oct’17 for MCL, prior treated with 1L therapy with its expected regulatory submission in H2’19

Click here to read full press release/ article | Ref: AstraZeneca | Image: Biotech Pharma Summit